Genoa Pharmaceuticals, Inc.
Genoa Pharmaceuticals, Inc. is listed today as Avalyn Pharma Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2023 | $189 M | No. 4 | $50 to $250 million | equity | SEC | |
| Apr 2020 | $36 M | No. 3 | $10 to $50 million | equity | SEC | |
| Mar 2017 | $18 M | No. 2 | $10 to $50 million | equity | SEC | |
| Oct 2011 | $2 M | No. 1 | $2 to $10 million | equity, debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Genoa Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2023).
SEC Form D · Oct 2023
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Oct 2023
That is all the official record says: Genoa Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Genoa Pharmaceuticals, Inc. are on record.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C-1, C-2 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series A, B, C-1, C-2 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| SR One Capital Management, LLC | Fund or asset manager | not stated | not stated | Held Series C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Fund or asset manager | not stated | not stated | Held Series C-1 and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 46 investors.
Largest shareholders today
Institutions holding Avalyn Pharma Inc. shares, as of Sep 30, 2026.
- FMR LLC$176 M13.95%
- Novo Holdings A/s$98 M7.78%
- SR One Capital Management, LP$94 M7.46%
- Perceptive Advisors LLC$76 M6.03%
- Montanova Capital, LLC$71 M5.65%
- NVP Associates, LLC$65 M5.12%
- Wellington Management Group LLP$60 M4.75%
- Price T Rowe Associates Inc /MD/$52 M4.09%
- T. Rowe Price Investment Management, Inc.$50 M3.97%
- Catalio Capital Management, LP$48 M3.83%
- Eventide Asset Management, LLC$39 M3.10%
- Bellevue Group AG$38 M3.05%
- BlackRock, Inc.$38 M2.99%
- Soleus Capital Management, L.P.$29 M2.30%
- Citadel Advisors LLC$27 M2.16%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Lyn Baranowski | Executive officer | Oct 2023 |
| A. Bruce Montgomery | Executive officer | May 2020 |
| Bruce W. Montgomery, M.D. | Executive officer | May 2017 |
| Mark W. Surber, Ph.D. | Executive officer | May 2017 |
| Bruce G. Montgomery, M.D. | Executive officer | Mar 2017 |
| Richard G. Vincent | Executive officer | Mar 2017 |
| Michael J. Kamdar | Executive officer | Nov 2012 |
| Cassandra Gianna Luca | Director | Oct 2023 |
| Jill Gianna Carroll | Director | Oct 2023 |
| Jonathan Leff | Director | Oct 2023 |
| Ketan Patel | Director | Oct 2023 |
| Lyn Baranowski | Director | Oct 2023 |
| Niall O'Donnell | Director | Oct 2023 |
| Peter Moldt | Director | Oct 2023 |
| Tiba Aynechi | Director | Oct 2023 |
| A. Bruce Montgomery | Director | May 2020 |
| Heather Bruce Preston | Director | May 2020 |
| Jonathan Bruce Leff | Director | May 2020 |
| Ketan Bruce Patel | Director | May 2020 |
| Niall Bruce O'Donnell | Director | May 2020 |
| Robert Bruce Mittendorff | Director | May 2020 |
| Sofia Bruce Ioannidou | Director | May 2020 |
| Tiba Bruce Aynechi | Director | May 2020 |
| Bruce W. Montgomery, M.D. | Director | May 2017 |
| Heather W. Preston | Director | May 2017 |
| Jonathan W. Leff, M.D. | Director | May 2017 |
| Ketan W. Patel | Director | May 2017 |
| Naveed W. Siddiqi | Director | May 2017 |
| Niall W. O'Donnell | Director | May 2017 |
| Tiba W. Aynechi | Director | May 2017 |
| Bruce G. Montgomery, M.D. | Director | Mar 2017 |
| Jonathan G. Leff, M.D. | Director | Mar 2017 |
| Ketan G. Patel | Director | Mar 2017 |
| Naveed G. Siddiqi | Director | Mar 2017 |
| Niall G. O'Donnell | Director | Mar 2017 |
| Tiba G. Aynechi | Director | Mar 2017 |
| Daniel D. Burgess | Director | Aug 2015 |
| Mark W. Surber, Ph.D. | Director | Aug 2015 |
| Michael J. Kamdar | Director | Aug 2015 |
Went public since 2026. Its SEC number is that of a company listed on a stock exchange.